Abstract: This description relates to a molecular marker for early pancreatic neoplasm detection, a detection method and use thereof. The pancreatic cancer marker miRNAs: miR-30c, miR-24, miR-23a and miR-132. The combination, method and kit provided by the present invention can be used for screening and differential diagnosis of early pancreatic cancer, monitoring of disease complications and recurrence, evaluation of curative effect, drug efficacy and guidance of precise drug use, etc., and it has the advantages of a wide detection spectrum, high sensitivity, good specificity, low detection cost, convenient material acquisition, and easy storage of samples. This method can be widely used in the early screening and prognosis of pancreatic cancer, improving the low specificity and low sensitivity caused by the individual differences that are difficult to overcome due to the instability of a single marker or biomarkers currently widely used in clinical practice.

Abstract: The present invention provides methods for increasing sensitivity of cancer cells to an antiestrogen agent, such as a selective estrogen receptor modulator (SERM). The methods include administering to the subject a polynucleotide in an amount effective to increase the antiestrogen agent sensitivity of the cancer cells. The cancer cells may be estrogen receptor positive, such as ER-?66 positive or ER-?36 positive, prior to the administering. Also provided are methods for decreasing the amount of estrogen receptor present in a cancer cell, methods for determining whether antiestrogen agent sensitivity of cancer cells in a subject can be increased, methods for diagnosing whether a subject has, or is at risk for developing, cancer, and methods for identifying an agent that increases the amount of let-7 miRNA in a cell.

Abstract: A method including isotope labeling of a newly synthesized protein in a sufficient quantity such that a newly synthesized protein spectra and the pre-existing protein spectra are sufficiently separated. A further method including determining a ratio of a new and a pre-existing protein from mass spectra obtained by using mass spectrometry. In this method a resultant spectrum may be presented as integrated peak heights for a corresponding mass to charge ratio in the “centroid” mode.

Abstract: The present invention provides methods for increasing sensitivity of cancer cells to an antiestrogen agent, such as a selective estrogen receptor modulator (SERM). The methods include administering to the subject a polynucleotide in an amount effective to increase the antiestrogen agent sensitivity of the cancer cells. The cancer cells may be estrogen receptor positive, such as ER-?66 positive or ER-?36 positive, prior to the administering. Also provided are methods for decreasing the amount of estrogen receptor present in a cancer cell, methods for determining whether antiestrogen agent sensitivity of cancer cells in a subject can be increased, methods for diagnosing whether a subject has, or is at risk for developing, cancer, and methods for identifying an agent that increases the amount of let-7 miRNA in a cell.

Abstract: A method including isotope labeling of a newly synthesized protein in a sufficient quantity such that a newly synthesized protein spectra and the pre-existing protein spectra are sufficiently separated. A further method including determining a ratio of a new and a pre-existing protein from mass spectra obtained by using mass spectrometry. In this method a resultant spectrum may be presented as integrated peak heights for a corresponding mass to charge ratio in the “centroid” mode.